Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03594045 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03594045: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT03594045 is a Phase 2 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03594045, a Phase 2 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This research study is studying a drug as a possible treatment for heparin induced thrombocytopenia (HIT) or Heparin-induced Thrombocytopenia and Thrombosis (HITT). The drug involved in this study is apixaban.
Interventions
- DRUG Apixaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-12-18 |
| Est. Completion | 2019-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03594045
The ClinicalTrials.gov registry entry for NCT03594045 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Apixaban is the first listed.
NCT03594045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03594045 about?
NCT03594045 is a clinical study titled "Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)". This research study is studying a drug as a possible treatment for heparin induced thrombocytopenia (HIT) or Heparin-induced Thrombocytopenia and Thrombosis (HITT). The drug involved in this study is apixaban.
What is the current status of trial NCT03594045?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2018-12-18. Estimated completion is 2019-10-30.
What interventions are being tested in trial NCT03594045?
The interventions under investigation include: Apixaban (DRUG).
Who is sponsoring clinical trial NCT03594045?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.